Welcome to our dedicated page for Teva Pharmaceutical Industries SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Teva Pharmaceutical Industries's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Teva Pharmaceutical Industries's regulatory disclosures and financial reporting.
Teva Pharmaceutical Industries files its Annual Report on Form 10-K, outlining a global biopharmaceutical business built on generics, biosimilars and innovative medicines across three segments: United States, Europe and International Markets.
The company highlights key branded CNS products such as AUSTEDO, AJOVY, UZEDY and COPAXONE, plus oncology and respiratory franchises, while expanding a broad biosimilars portfolio through collaborations with Samsung Bioepis, Formycon, Prestige Biopharma and others. Teva reports a 2025 workforce of 33,950 employees in 57 countries and 1,149,812,898 ordinary shares outstanding as of December 31, 2025.
Management emphasizes its “Pivot to Growth” strategy, including focus on high-value and complex generics, divestiture of the API business, AI-driven efficiency initiatives, and continued network optimization. The filing also details extensive U.S., European and international regulatory frameworks, including the Inflation Reduction Act’s impact on AUSTEDO Medicare pricing from 2027 and Teva’s ongoing legal challenge to aspects of the program.
Teva Pharmaceutical Industries executive Eliyahu Sharon Kalif, EVP and Chief Financial Officer, received 141,478 restricted share units on January 27, 2026. These units were granted at a price of $0.00 per unit.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. The units were issued after performance criteria were met and remain subject to time-based vesting, scheduled to vest on March 3, 2026. The ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.
Teva Pharmaceutical Industries executive Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer, received 141,478 restricted share unitsJanuary 27, 2026. Each unit represents a right to receive one ordinary share or, at the committee’s option, the cash value of one share.
The restricted share units were earned after performance criteria were met and remain subject to time-based vesting, scheduled to vest on March 3, 2026. Following this award, Hughes directly beneficially owned 141,478 derivative securities tied to Teva ordinary shares.
Teva Pharmaceutical Industries Ltd. executive Mark Sabag reported an equity award of 141,478 restricted share units effective January 27, 2026. Each unit represents a contingent right to receive one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.
The restricted share units were received upon satisfaction of performance criteria tied to performance share units and remain subject to time-based vesting. These units are scheduled to vest on March 3, 2026. Following this award, Sabag directly beneficially owned 141,478 derivative securities linked to Teva ordinary shares.
Teva Pharmaceutical Industries Ltd. reported that Exec. VP, European Commercial, Richard Daniell was granted 141,478 restricted share units (RSUs) on January 27, 2026. Each RSU represents a right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The RSUs were earned upon satisfaction of performance criteria tied to earlier performance share units and remain subject to time-based vesting. They are scheduled to vest on March 3, 2026. The underlying ordinary shares may be represented by American Depositary Shares, with each ADS currently equal to one ordinary share.
Teva Pharmaceutical Industries’ President and CEO Richard D. Francis received new equity-based awards in the form of restricted share units (RSUs). On January 27, 2026, he was granted 620,110 RSUs that were earned after meeting performance criteria and will continue to vest on February 15, 2026. He was also granted an additional 891,315 RSUs that were earned upon satisfaction of separate performance goals and will vest on March 3, 2026.
Each RSU represents a contingent right to receive either one Teva ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. These awards are held directly by Francis and compensate performance while tying a significant portion of his compensation to Teva’s equity.
Teva Pharmaceutical Industries Limited furnished an update on its business performance by submitting an 8-K tied to its latest earnings release. On January 28, 2026, the company issued a press release detailing financial results for the period ended December 31, 2025, covering both full-year 2025 and fourth quarter performance. This press release is provided as Exhibit 99.1 and is incorporated by reference into the report, but the underlying financial figures and metrics appear only in the exhibit itself. The 8-K specifies that this earnings information is being furnished rather than filed, which affects how it is treated under U.S. securities laws.
Teva Pharmaceutical Industries Limited furnished an update on its expected performance for the 2025 fiscal year in connection with its presentation at the 44th Annual J.P. Morgan Healthcare Conference. On January 11, 2026, the company issued a press release outlining these expectations ahead of its January 13, 2026 conference presentation, and attached that release as an exhibit. The information is being provided to regulators for disclosure purposes and is expressly designated as furnished rather than filed under U.S. securities laws.
An officer of Teva Pharmaceutical Industries Ltd. reported selling 12,300 ordinary shares on 12/16/2025 at a weighted average price of $30.2036 per share. The filing identifies the insider as the company’s Chief Accounting Officer, and shows that 5,650 shares were beneficially owned directly after the transaction. The ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share. The sale was executed in multiple trades at prices ranging from $30.20 to $30.205 per share.
Teva Pharmaceutical Industries Ltd. director Roberto Mignone reported selling 77,400 Ordinary Shares of Teva on 12/16/2025 at a weighted average price of $30.2409 per share. The filing notes that Teva’s Ordinary Shares may be represented by American Depositary Shares, each currently equal to one Ordinary Share.
After this sale, the report shows Mr. Mignone with 105,315 Ordinary Shares held directly. It also shows 367,600 Ordinary Shares held of record by Swiftcurrent Master Fund Ltd., for which Bridger Management, LLC is investment adviser and Mr. Mignone is manager. Under SEC rules he may be deemed to beneficially own those shares, but he disclaims beneficial ownership except to the extent of his indirect pecuniary interest.